Open | $64.970 |
Close | $65.370 |
Volume / Avg. | 488.612K / 827.504K |
Day Range | 64.750 - 65.980 |
52 Wk Range | 43.180 - 76.110 |
Market Cap | $6.328B |
P/E Ratio | - |
Dividend Yield | - |
Exchange | NASDAQ |
RSI | 42 |
Short Interest | 4.62% |
Days to Cover | 4.76 |
Name |
---|
Revenue Change |
Gross Change |
EBITDA Change |
EBIT Change |
Earnings Change |
You can purchase shares of Intra-Cellular Therapies (NASDAQ: ITCI) through any online brokerage.
Other companies in Intra-Cellular Therapies’s space includes: Novo Nordisk (NYSE:NVO), Johnson & Johnson (NYSE:JNJ), Merck & Co (NYSE:MRK), CymaBay Therapeutics (NASDAQ:CBAY) and Novartis (NYSE:NVS).
The latest price target for Intra-Cellular Therapies (NASDAQ: ITCI) was reported by Cantor Fitzgerald on Friday, February 23, 2024. The analyst firm set a price target for 101.00 expecting ITCI to rise to within 12 months (a possible 54.51% upside). 36 analyst firms have reported ratings in the last year.
The stock price for Intra-Cellular Therapies (NASDAQ: ITCI) is $65.37 last updated March 18, 2024 at 4:00 PM EDT.
There are no upcoming dividends for Intra-Cellular Therapies.
Intra-Cellular Therapies’s Q1 earnings are confirmed for Thursday, May 2, 2024.
There is no upcoming split for Intra-Cellular Therapies.
Intra-Cellular Therapies is in the Health Care sector and Pharmaceuticals industry. They are listed on the NASDAQ.